2007-2012 Partnering within Pancreatic Cancer Industry Examined by CurrentPartnering
14 Mar 2012 • by Natalie Aster
Thorough analysis of pancreatic cancer partnering deals is presented in new CurrentPartnering report “Pancreatic Cancer Partnering 2007-2012” that provides understanding and access to the pancreatic cancer partnering deals and agreements entered into by the world leading healthcare companies.
The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pancreatic cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Pancreatic Cancer Partnering 2007-2012
Published: February, 2012
Price: US$ 995,00
This data driven report contains over 80 links to online copies of actual pancreatic cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
More information can be found in the report “Pancreatic Cancer Partnering 2007-2012” by CurrentPartnering.
To order the report or ask for sample pages contact [email protected]